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Abstract 
Background: Allergic diseases such as asthma and allergic rhinitis constitute asignificant burden of disease among 
women of childbearing age and those who arepregnant. Adequately managing these conditions is paramount in 
reducing negativefetal outcomes as well as maternal complications during pregnancy. However, thepotential for 
harm to both the mother and fetus demands carefully balancing efficacyand safety of treatment. Allergen immuno-
therapy (AIT) has emerged as a relativelysafe and efficacious mode of therapy in both children and adults. AIT has also 
beenconsidered for use during pregnancy.
Methods: A review of the literature wasconducted for data regarding the safety of initiation and continuation of AIT 
duringpregnancy as well as the effect of AIT on the development of atopy in offspring. MEDLINE and the Cochrane 
Library were searched for clinical trials, randomizedcontrol trials, observational studies and journal articles in English 
using the terms"Pregnancy" and "Immunotherapy" from 1900 to present. This yielded 4 studies(totaling 422 preg-
nancies receiving AIT) investigating the continuation of AIT inpregnancy, 2 (totaling 31 pregnancies receiving AIT) 
evaluating AIT initiation duringpregnancy and 5 observing the effect of AIT on atopy in offspring.
Results: No significant difference was found in the incidence of prematurity,hypertension (HTN)/proteinuria, congen-
ital malformations or perinatal deaths betweenthe women continued on AIT (both subcutaneous (SC) IT and sublin-
gual (SL) IT toinhalant allergens as well as venom IT) during pregnancy and controls. Similarly, therewas no significant 
difference in maternal or fetal complications between pregnantwomen initiated on AIT and controls. Among the few 
pregnant women (10/453pregnancies) who experienced generalized reactions while receiving AIT, none werefound 
to have fetal complications. Neither SCIT nor SLIT during pregnancy altered therisk of developing atopic disease in 
offspring.
Conclusions: Based on these data, the continuation of AIT during pregnancyappears safe. Furthermore, the few data 
available suggest that the initiation of AITduring pregnancy might also be safe, however, more data is required for 
a definitiveconclusion. Lastly, available studies do not show a convincing reduction in thedevelopment of atopy in 
offspring from the administration of AIT during pregnancy.
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Background
Asthma and allergic rhinitis are a significant cause of 
morbidity among women of childbearing age, including 
those who are pregnant. As many as 20–30 % of repro-
ductive age women are affected by these atopic condi-
tions [1, 2], with approximately one-third of women 
experiencing worsening of nasal and/or asthmatic symp-
toms during pregnancy [2–4]. Among women who are 
pregnant, 18–30 % suffer from symptoms of rhinitis and/
or sinusitis [2], while up to 8.8 % are afflicted by asthma 
[5], and the prevalence continues to rise [5, 6]. Further-
more, up to 20 % of these women experience asthmatic 
exacerbations, resulting in hospitalization or even death 
[7]. Aside from asthma and allergic rhinitis, other aller-
gic conditions such as Hymenoptera venom allergy also 
contribute to the burden of allergic disease in pregnant 
women [8].
Adequately controlling asthma during pregnancy 
is critical for the health of both the mother and fetus. 
Uncontrolled persistent asthma with frequent exacerba-
tions has been associated with negative fetal outcomes 
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such as low birthweight [7] and congenital malforma-
tions [9], as well as complications for the mother includ-
ing pre-eclampsia, gestational diabetes and antepartum 
hemorrhage [9, 10]. Successfully controlling allergic rhi-
nitis is also important, as uncontrolled rhinitis can not 
only impair sleep and overall quality of life, but can also 
worsen the symptoms of asthma [2, 11].
According to the National Asthma Education and Pre-
vention Program 2004 guidelines, the conventional treat-
ment of asthma in pregnancy consists of salbutamol and 
inhaled corticosteroids (budesonide in particular) plus or 
minus long-acting beta-2 agonists, as well as theophyl-
line and leukotriene antagonists as adjuncts, depending 
on severity [12]. While a few studies have reported an 
increased risk to the fetus in the form of congenital mal-
formations [13–15], the overall data supports the safety 
of these conventional agents, and given the substantial 
risk of poorly controlled asthma to the fetus, their use is 
generally recommended [12, 16].
Another widely used modality for the treatment of 
asthma and allergic rhinitis is allergen immunotherapy 
(AIT). Subcutaneous allergen immunotherapy (SCIT) was 
initially developed in the early 1900s, when it was first 
described by Noon that the injection of grass pollen extract 
reduced the symptoms of hay fever [17]. By contrast, the 
first randomized trial of sublingual allergen immunother-
apy (SLIT) was published in 1986 [18]. Since then, SLIT 
has been increasingly used in Europe and more recently in 
the United States and Canada with approval of Oralair®, 
Grastek® and Ragwitek®. In addition to asthma and aller-
gic rhinitis, AIT is also commonly used for the treatment 
of Hymenoptera allergy. Despite the widespread use of AIT, 
however, few data exist regarding its safety in pregnancy.
This review outlines the existing data surrounding the 
initiation and continuation of AIT during pregnancy, 
focusing on safety for the mother and fetus, as well as 
future atopic outcomes for the offspring.
Continuation of immunotherapy during pregnancy
The earliest controlled study to describe the use and 
safety of AIT in pregnancy was published in 1978 by 
Metzger et al. [19]. Metzger et al. conducted a retrospec-
tive analysis of 90 atopic women (mostly allergic rhinitis 
and asthma) who had undergone SCIT during one or 
more pregnancies, for a total of 121 pregnancies. Most 
of the pregnancies occurred after the initiation of SCIT, 
although the exact proportions were not reported. No 
significant difference was found in the incidence of pre-
maturity, hypertension (HTN)/proteinuria or congenital 
malformations between the treated and control groups 
[19]. Furthermore, among the 7 generalized reactions 
observed in the treated group, none resulted in abnormal 
births [19]. These data were the earliest to suggest that 
SCIT was safe for continuation during pregnancy.
In a later study, Shaikh et al. retrospectively evaluated 
81 atopic Indian women (again primarily allergic rhini-
tis and asthma) who had become pregnant one or more 
times during SCIT, for a total of 109 pregnancies, 102 of 
which were in women receiving SCIT prior to becom-
ing pregnant [20]. As compared to the control group, the 
incidence of prematurity and HTN/proteinuria was actu-
ally lower in the group of women continuing SCIT dur-
ing pregnancy [20]. Of the 3 patients who were observed 
to have a systemic reaction in response to SCIT, none 
were found to have any complications with the birth. 
Thus, as previously described by Metzger et al., continu-
ation of SCIT during pregnancy was not associated with 
increased risk to the mother or fetus.
Since the first randomized control trial of SLIT in 1986, 
there have been more than fifty double-blind placebo 
controlled trials published demonstrating SLIT efficacy 
in children and adults. However, only one trial has thus 
far been conducted to evaluate its safety in pregnancy 
[21]. Shaikh et  al. prospectively evaluated 280 atopic 
women (primarily allergic rhinitis and asthma) who 
had become pregnant one or more times, for a total of 
326 pregnancies. These women were given the option of 
receiving either SLIT, budesonide or rescue salbutamol 
alone (controls). Of the 185 pregnancies receiving SLIT, 
161 were continuations that were initiated prior to preg-
nancy. No significant difference in perinatal deaths, pre-
maturity, HTN/proteinuria or congenital malformations 
were observed between the group of women continuing 
SLIT during pregnancy and controls [21]. Furthermore, 
no systemic reactions were noted in response to SLIT. 
This study suggests that SLIT is also a safe and viable 
option for continuation during pregnancy.
Most of the studies evaluating the safety of AIT in 
pregnancy focused on women suffering from allergic rhi-
nitis and/or asthma. By contrast, Schwartz et al. was the 
first and only group to investigate the effects of venom 
immunotherapy (VIT) in Hymenoptera-allergic preg-
nant patients [8]. Schwartz et al. retrospectively analyzed 
26 women with a history of prior systemic reaction to 
Hymenoptera venom, who had become pregnant one or 
more times during VIT, for a total of 43 pregnancies, 38 
of which were in women already receiving maintenance 
doses prior to pregnancy. No significant difference in 
maternal/fetal complications was observed between the 
38 women receiving VIT prior to pregnancy as compared 
to the general population [8]. No major systemic reac-
tions were observed. Thus, in addition to AIT for allergic 
rhinitis and asthma, VIT may also be safe for the continu-
ation in pregnant women.
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Initiation of immunotherapy during pregnancy
As compared to the continuation of AIT during preg-
nancy, data regarding the effects of initiation are scarce. 
In the retrospective study by Shaikh et  al., of 81 atopic 
Indian women who had become pregnant one or more 
times during SCIT, only 7 of the total 109 pregnancies 
had been in women receiving AIT for the first time during 
pregnancy [20]. None of these pregnancies were found to 
have any maternal or fetal complications as compared to 
controls [20]. Of the 3 patients who had experienced sys-
temic reactions, only one had been started on AIT during 
pregnancy, and no complications were observed [20].
Shaikh et al. observed similar findings in their prospec-
tive study of SLIT during pregnancy [21]. Twenty-four of 
the 185 pregnancies in which women received SLIT were 
first starts during pregnancy. Similar to the women in 
whom SLIT was initiated prior to pregnancy, no systemic 
reactions or increased maternal/fetal complications were 
observed as compared to controls [21].
Immunotherapy and atopy in offspring
Although the precise mechanisms behind AIT are still 
being elucidated, it is known that the levels of allergen-
specific IgG increase during treatment and are thought 
to mirror changes to the allergic response, potentially via 
competing with IgE for binding to allergen [22]. These 
allergen-specific IgG antibodies induced by AIT have 
been found to cross the placenta during pregnancy [23], 
and their levels in cord blood have been associated with 
reduced atopy in offspring [24].
While these correlative data suggest that AIT during 
pregnancy might reduce the risk of developing atopy in 
offspring, several studies have failed to demonstrate such 
benefit. In the study by Metzger et al. who evaluated 109 
offspring (1/3 of which were <2 years old) of atopic moth-
ers who received SCIT, 24.7 % exhibited allergic rhinitis or 
asthma [19] which was similar in incidence to the general 
population of children with an atopic parent. Similarly, in 
the retrospective study by Shaikh et al., 16 of the 60 chil-
dren (age 5 months–5 years) born from mothers receiving 
SCIT during pregnancy had symptoms of atopic disease, 
which again was consistent with the incidence in children 
with one atopic parent [20]. Finally, in a study by Settipane 
et al. 38 % (15/40) of children (followed for >10 years) born 
from mothers who had received SCIT during pregnancy, 
and 45  % (17/38) of those born from untreated mothers 
developed asthma/allergic rhinitis, which was a non-statis-
tically significant difference [25]. Thus, these studies sug-
gest that continuing SCIT during pregnancy does not alter 
the risk of developing atopic disease in offspring.
Data surrounding the effect of SLIT on the develop-
ment atopy in offspring is more limited. In the only 
published study using SLIT, Shaikh et  al. evaluated 176 
children of mothers treated with SLIT and found 24.42 % 
of children compared to 25.32 and 23.53 % in the budeso-
nide and rescue salbutamol control groups, respectively, 
had symptoms of atopic disease, again with no difference 
from the incidence in the general population [21].
In a more recent retrospective survey study, Todd et al. 
evaluated 143 mothers with allergic rhinitis, some of 
which received AIT (unspecified whether SCIT or SLIT) 
during or prior to pregnancy, for the development of any 
allergic disease in offspring. Of the 277 children born to 
these mothers, a lower risk of allergic disease was seen in 
offspring from mothers receiving AIT during (OR = 0.84) 
or before (OR = 0.83) pregnancy as compared to atopic 
mothers not receiving AIT. Controlling for confounding 
variables (including breastfeeding, father’s allergic status 
etc.), however, these data were not found to be statisti-
cally significant [26].
Conclusions
From the data described herein, it appears that the con-
tinuation of AIT during pregnancy is safe to both the 
mother and fetus. Indeed, according to the AAAAI/
ACAAI Joint Task Force guidelines on AIT, as well as the 
EAACI, it is recommended that maintenance AIT may be 
continued during pregnancy [27, 28].
The data surrounding the initiation of AIT is limited. 
In each of the studies evaluating AIT during pregnancy, 
only a small proportion of the women were initiated 
on AIT during pregnancy. As such, both the AAAAI/
ACAAI Joint Task Force and EAACI discourage the ini-
tiation of AIT during pregnancy until more data is avail-
able [27, 28]. A similar practice is followed in Canada.
Although there were no maternal/fetal complications 
observed in those few pregnant mothers who experienced 
generalized reactions in response to AIT, some studies 
have reported significant morbidity or even mortality from 
anaphylaxis during pregnancy [29, 30]. Thus, the benefits 
derived from AIT in pregnancy must be carefully balanced 
with the risk of anaphylaxis. Among non-pregnant patients, 
non-fatal or fatal reactions from subcutaneous injections of 
aeroallergens are rare with an incidence of <1 in one mil-
lion [31]. By contrast, rates of systemic reactions with VIT 
have been reported to be as high as 5 % during the induction 
phase and 1 % during maintenance [8]. Despite these higher 
rates, however, the risk of VIT in pregnancy may still be jus-
tified given that treatment of sensitized women may reduce 
the risk of re-sting anaphylaxis from as high as 74 to 1–2 % 
[8, 32]. Thus, although the AAAAI/ACAAI Joint Task Force 
generally discourages initiation of AIT during pregnancy, it 
may still be considered in special high-risk scenarios such as 
women with prior anaphylaxis to Hymenoptera venom [27].
Page 4 of 5Oykhman et al. Allergy Asthma Clin Immunol  (2015) 11:31 
With respect to any potential benefit from AIT during 
pregnancy in reducing the development of atopy in off-
spring, the few studies that have been conducted thus far 
suggest no protective effect on the development of atopic 
disease. However, the protective trend seen in a recent 
survey study [26] highlights the need for more studies 
before a definitive conclusion can be generated. At this 
time, however, the guidelines do not endorse AIT for pri-
mary prevention of atopy in offspring [27].
Given the significant burden and growing prevalence 
of allergic disease among women of childbearing age 
and those who are pregnant, allergists will be increas-
ingly faced with having to make treatment decisions in 
this population. Given the potential for harm to both the 
mother and fetus from treatment, balancing safety and 
efficacy will be paramount. AIT has emerged as a signifi-
cant and efficacious mode of therapy for allergies includ-
ing allergic rhinitis, asthma and Hymenoptera venom, 
and from the studies presented herein, may serve as a 
safe and viable option in pregnancy.
Key take‑home messages
  • Continuation of AIT during pregnancy appears to be 
safe for both the mother and fetus
  • Given the paucity of data regarding safety, AIT 
should generally not be initiated during pregnancy, 
with the exception of high-risk scenarios such as 
women with prior anaphylaxis to Hymenoptera 
venom where the benefits may outweigh the risks
  • At this time, there is no convincing data to suggest a 
benefit from AIT in preventing the development of 
atopy in offspring, and as such, AIT should not be 
used exclusively for this purpose
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